Dual therapy for third-lineHelicobacter pylorieradication and urea breath test prediction

摘要: We evaluated the efficacy and tolerability of a dual therapy with rabeprazole amoxicillin (AMX) as an empiric third-line rescue therapy. In patients failure first-line treatment proton pump inhibitor (PPI)-AMX-clarithromycin regimen second-line PPI-AMX-metronidazole regimen, eradication (10 mg q.i.d.) AMX (500 was prescribed for 2 wk. Eradication confirmed by results ¹³C-urea breath test (UBT) at 12 wk after A total 46 were included; however, two lost to follow-up. The rates determined per-protocol intention-to-treat analyses 65.9% 63.0%, respectively. pretreatment UBT in subjects showing failure; those successful comprised 32.9 ± 28.8 permil 14.8 12.8 permil, significantly higher than (P = 0.019). low result (≤ 28.5 permil) predicted success positive predictive value 81.3% sensitivity 89.7%. Adverse effects reported 18.2% patients, mainly diarrhea stomatitis. Dual appears serve potential empirical strategy values on UBT.